Fragment-based screening with natural products for novel anti-parasitic disease drug discovery

Expert Opin Drug Discov. 2019 Dec;14(12):1283-1295. doi: 10.1080/17460441.2019.1653849. Epub 2019 Sep 12.

Abstract

Introduction: Fragment-based drug discovery can identify relatively simple compounds with low binding affinity due to fewer binding interactions with protein targets. FBDD reduces the library size and provides simpler starting points for subsequent chemical optimization of initial hits. A much greater proportion of chemical space can be sampled in fragment-based screening compared to larger molecules with typical molecular weights (MWs) of 250-500 g mol-1 used in high-throughput screening (HTS) libraries. Areas covered: The authors cover the role of natural products in fragment-based drug discovery against parasitic disease targets. They review the approaches to develop fragment-based libraries either using natural products or natural product-like compounds. The authors present approaches to fragment-based drug discovery against parasitic diseases and compare these libraries with the 3D attributes of natural products. Expert opinion: To effectively use the three-dimensional properties and the chemical diversity of natural products in fragment-based drug discovery against parasitic diseases, there needs to be a mind-shift. Library design, in the medicinal chemistry area, has acknowledged that escaping flat-land is very important to increase the chances of clinical success. Attempts to increase sp3 richness in fragment libraries are acknowledged. Sufficient low molecular weight natural products are known to create true natural product fragment libraries.

Keywords: 3D shape; anti-parasitic; chemical diversity; fragment-based drug discovery; malaria proteome; native mass spectrometry; natural product-like; natural products.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiparasitic Agents / chemistry
  • Antiparasitic Agents / pharmacology*
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Chemistry, Pharmaceutical
  • Drug Discovery / methods*
  • High-Throughput Screening Assays
  • Humans
  • Molecular Weight
  • Parasitic Diseases / drug therapy*
  • Parasitic Diseases / parasitology
  • Small Molecule Libraries

Substances

  • Antiparasitic Agents
  • Biological Products
  • Small Molecule Libraries

Grants and funding

The authors are funded by: the Australian Research Council (grant numbers DP 160101429 and DP130102400), the Bill and Melinda Gates Foundation (grant numbers OPP1008376 and OPP1035218) and the National Health and Medical Research Council (Grant number APP1046715).